BioCentury
ARTICLE | Clinical News

Brilinta not significantly better than clopidogrel in PAD

October 4, 2016 7:00 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor missed the primary endpoint in the global Phase III EUCLID trial. The anticoagulant failed to significantly reduce major cardiovascular events in patients with peripheral arterial disease compared with generic drug clopidogrel.

EUCLID's primary endpoint was time to first occurrence of cardiovascular death, myocardial infarction (MI) or ischemic stroke. The study enrolled 13,885 symptomatic PAD patients. AstraZeneca said detailed data are to be presented at the American Heart Association meeting in November. ...